Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva + Capecitabine in Previously Treated Metastatic Pancreatic Cancer
NCT00125021Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2003
- Primary completion
- Jun 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Response Rate. Started Oct 2003; status: completed.
02
Drugs
erlotinib
Beyond the preview
Go deeper on NCT00125021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00125021.